<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670552</url>
  </required_header>
  <id_info>
    <org_study_id>NIPEMS1111</org_study_id>
    <nct_id>NCT01670552</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients</brief_title>
  <official_title>Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of an association with one
      anti-inflammatory and one gastroprotective agent compared to the anti-inflammatory
      monotherapy in patients with acute or chronic osteoarticular inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Double-blind,randomized, multicenter

        -  Experiment duration: 8 days

        -  03 visits (day 0 - screening), (day 1 - randomization), (day 7 - closure)

        -  Evaluate the safety of an association with one anti-inflammatory and one
           gastroprotective compared to anti-inflammatory monotherapy in patients with acute or
           chronic osteoarticular inflammation

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of endoscopic and histological changes of the upper gastrointestinal tract</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and dyspeptic complaints during the study</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Acute and Chronic Inflammation</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Nimesulide + Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimesulide + Pantoprazole- 1 tablet each 12 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimesulide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nimesulide- 1 tablet each 12 hours for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimesulide + Pantoprazole</intervention_name>
    <description>1 tablet each 12 hours for 7 days</description>
    <arm_group_label>Nimesulide + Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimesulide</intervention_name>
    <description>1 tablet each 12 hours for 7 days</description>
    <arm_group_label>Nimesulide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults male or female aged â‰¥ 18 years old;

          -  Comply with all the purposes and procedures of the study by signing and dating the IC

          -  Acute or chronic osteo-articular injury in need of of anti-inflammatory for a period
             of 7 days

          -  Upper endoscopy with normal or non-erosive esophagitis or gastritis endoscopic
             enanthematous.

        Exclusion Criteria:

          -  Pregnant women, or women in childbearing age who are not in use effective
             contraception or intending to become pregnant during the study period History of
             peptic ulcer or gastric surgery;

               -  Use of Non-steroidal anti-inflammatory (NSAIDs), aspirin, proton pump inhibitor
                  (PPIs), H2 blocker and antacid in the past 30 days;

               -  Upper endoscopy with erosive lesions or ulcerated lesions of the esophagus,
                  stomach and / or duodenum;

               -  Contraindication to the use of NSAIDs or PPIs;

               -  Renal or hepatic impairment;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Nimesulide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
